Straits Times Index
3,322.08 -8.69 (-0.26%) Nikkei
39,329.45 +291.29 (+0.75%) Hang Seng
18,366.95 -109.85 (-0.59%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
69,369.37 -170.64 (-0.25%) CMC Crypto 200
1,438.93 -7.74 (-0.54%)
RARE Nov 2024 25.000 put
| Previous close | 0.7500 |
| Open | 0.7500 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 25.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.7500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 24 |
GlobeNewswireUltragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's chief executive officer, will participate in a fireside at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 10:00 a.m. ET. The live and archived webcast of t
ZacksUltragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
- GlobeNewswire
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m. ET NOVATO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced positive topline results from the Phase 3 GlucoGene study (NCT05139316) evaluating DTX401, an investigational gene therapy for the treatment of patients aged eight years and olde
